Drug Price Trends for NDC 33342-0249

Average Pharmacy Cost for 33342-0249

Drug Name	NDC	Price/Unit ($)	Unit	Date
REPAGLINIDE 1 MG TABLET	33342-0249-11	0.08004	EACH	2026-03-18
REPAGLINIDE 1 MG TABLET	33342-0249-11	0.08033	EACH	2026-02-18
REPAGLINIDE 1 MG TABLET	33342-0249-11	0.08354	EACH	2026-01-21
REPAGLINIDE 1 MG TABLET	33342-0249-11	0.08981	EACH	2025-12-17
REPAGLINIDE 1 MG TABLET	33342-0249-11	0.09201	EACH	2025-11-19
REPAGLINIDE 1 MG TABLET	33342-0249-11	0.10051	EACH	2025-10-22
REPAGLINIDE 1 MG TABLET	33342-0249-11	0.09914	EACH	2025-09-17

Best Wholesale Price for NDC 33342-0249

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Biologics Market Analysis: NDC 33342-0249

Last updated: February 17, 2026

This report analyzes the market landscape and price projections for the drug identified by National Drug Code (NDC) 33342-0249. The analysis focuses on key market drivers, competitive pressures, and patent expiration timelines to forecast potential price trajectories.

What is NDC 33342-0249?

NDC 33342-0249 identifies a specific pharmaceutical product. The structure of an NDC, a 10 or 11-digit number, indicates the manufacturer, product, and package size. The first set of digits signifies the manufacturer, the middle digits identify the specific drug product, and the last digits denote the package size [1]. Without further proprietary or publicly accessible database access linking this specific NDC to its active pharmaceutical ingredient (API), therapeutic class, or brand name, a definitive identification of the drug is not possible through the NDC alone. However, the analysis proceeds by examining general market dynamics applicable to biologics, given the typical complexity and cost associated with such products.

What Therapeutic Areas Does NDC 33342-0249 Likely Target?

Biologics, often characterized by high development costs and specialized manufacturing, are predominantly used in complex therapeutic areas. Given the typical cost structure and market positioning of biologics, NDC 33342-0249 is likely to target one or more of the following:

• Oncology: Treatment of various cancers, including solid tumors and hematological malignancies.
• Immunology and Autoimmune Diseases: Management of conditions such as rheumatoid arthritis, psoriasis, Crohn's disease, and multiple sclerosis.
• Rare Diseases: Therapies for genetic disorders or conditions with limited patient populations.
• Endocrinology: Treatments for conditions like diabetes, growth hormone deficiency, or thyroid disorders.
• Cardiovascular Diseases: Management of chronic heart conditions or their contributing factors.

The specific therapeutic area is critical for understanding its associated market size, patient demographics, and competitive landscape.

What is the Current Market Size for Biologics in Relevant Therapeutic Areas?

The global biologics market is substantial and continues to expand, driven by increasing prevalence of chronic diseases, advancements in biotechnology, and a growing demand for targeted therapies.

Global Biologics Market Size (USD Billions)

Year	Market Size	Compound Annual Growth Rate (CAGR)	Source
2022	475	N/A	[2]
2023	515	8.4%	[3]
2024	560	8.7%	[3]
2027	750	7.8%	[2]

These figures represent the aggregate market for biologics. The specific market size for the therapeutic area addressed by NDC 33342-0249 would be a subset of these broader figures. For instance, the global oncology biologics market alone was valued at approximately USD 140 billion in 2022 [4]. The autoimmune disease biologics market is also a significant segment, estimated at over USD 80 billion [5].

What are the Key Market Drivers for Biologics?

Several factors contribute to the sustained growth of the biologics market:

• Increasing Prevalence of Chronic Diseases: Aging populations and lifestyle changes lead to a higher incidence of conditions like cancer, diabetes, and autoimmune disorders, increasing demand for advanced treatments [6].
• Technological Advancements: Innovations in genetic engineering, cell and gene therapy, and monoclonal antibody development enable the creation of more effective and targeted therapies [7].
• Personalized Medicine: The shift towards patient-specific treatments, often facilitated by biologics, enhances therapeutic outcomes and drives market growth [8].
• Pipeline Strength: A robust pipeline of novel biologic candidates in clinical development promises future market expansion and new treatment options [9].
• Regulatory Support: Expedited review pathways and orphan drug designations for biologics targeting rare diseases can accelerate market entry and adoption [10].

What are the Competitive Pressures Affecting Biologics like NDC 33342-0249?

The biologics market faces multifaceted competitive pressures:

• Branded vs. Biosimilar Competition: As blockbuster biologics lose patent protection, biosimilar versions enter the market, leading to price erosion and market share shifts. The regulatory pathways for biosimilar approval in major markets (e.g., U.S. FDA, EMA) are well-established [11].
• Pipeline Competition: Multiple companies often develop similar biologic agents targeting the same disease, leading to intense competition for market approval and patient adoption based on efficacy, safety, and tolerability profiles.
• Therapeutic Alternatives: Development of non-biologic drugs or alternative therapeutic modalities (e.g., small molecules, gene therapies) can offer competitive options, impacting market share.
• Pricing and Reimbursement: Payer scrutiny, formulary restrictions, and value-based pricing models influence market access and profitability. Manufacturers must demonstrate significant clinical and economic value to secure favorable reimbursement [12].
• Manufacturing Complexity and Cost: The intricate manufacturing processes for biologics can create barriers to entry but also present challenges in scaling production and managing costs, impacting competitive pricing strategies.

What is the Patent Landscape for Biologics?

The patent landscape for biologics is characterized by multiple layers of protection, including:

• Composition of Matter Patents: These patents cover the biologic molecule itself and are typically the strongest form of protection, often lasting 20 years from the filing date [13].
• Method of Use Patents: These patents protect specific indications or therapeutic applications of the biologic [13].
• Manufacturing Process Patents: These patents cover novel or improved methods of producing the biologic [13].
• Formulation Patents: These patents protect specific drug delivery systems or formulations that enhance stability, bioavailability, or patient convenience [13].
• Evergreening Strategies: Companies may employ strategies like seeking patents for new formulations, delivery devices, or indications to extend market exclusivity beyond the primary patent expiration.

The expiration of key patents, particularly composition of matter patents, is the primary trigger for biosimilar entry and subsequent price reduction. The timeline for patent expiration can vary significantly based on filing dates, patent term extensions, and any litigation outcomes.

How Do Patent Expirations Affect Biologic Pricing?

Patent expirations lead to a significant shift in pricing dynamics.

Projected Price Erosion Post-Patent Expiration for Biologics:

• Initial Biosimilar Entry: Upon the first biosimilar launch, prices of the originator biologic can decrease by 15-30% within the first year, depending on market penetration and payer policies [14].
• Increased Biosimilar Competition: As more biosimilars enter the market, price reductions can accelerate. This can lead to originator prices dropping by 40-70% or more within 3-5 years of the first biosimilar launch [15].
• Therapeutic Area Specifics: The degree of price erosion is also influenced by the therapeutic area. Markets with high unmet needs and limited treatment options may see slower price declines initially, while more crowded markets experience faster erosion [16].
• Reimbursement Policies: Payer incentives for using biosimilars, such as preferred formulary placement or rebates, significantly impact the speed and magnitude of price reductions [14].

What are the Price Projections for NDC 33342-0249?

Projecting precise prices for NDC 33342-0249 without knowing the specific drug, its therapeutic indication, its current market exclusivity status, and its patent expiration dates is not feasible. However, general trends for biologics can be applied.

Hypothetical Price Trajectory Framework for a Biologic (NDC 33342-0249):

1. Current Market Exclusivity Period (Years 0-X): During this period, with no direct biosimilar competition, the originator biologic is expected to maintain its premium pricing, influenced by factors like dosage, administration frequency, clinical value, and competitive landscape within its therapeutic class. Pricing can range from USD 10,000 to USD 500,000+ annually per patient, depending on the condition treated and treatment duration [17].
2. Anticipated Patent Expiration (Year X): The expiration of key patents.
3. Biosimilar Entry and Initial Price Adjustment (Years X+1 to X+3):
   • Price Decrease: Expect a price reduction for the originator product of 15-30% as the first biosimilars gain market approval and adoption.
   • Biosimilar Pricing: The initial price of the biosimilar is typically set 15-25% below the originator's price [14].
4. Increased Biosimilar Competition and Further Price Erosion (Years X+4 onwards):
   • Price Decrease: Further price erosion for both originator and biosimilar products, potentially reaching 40-70% or more compared to the pre-expiration price.
   • Market Dynamics: Pricing will stabilize based on the number of biosimilar competitors, payer negotiations, and evidence of real-world effectiveness.

Factors that would influence the specific trajectory:

• Complexity of the Biologic: More complex biologics with challenging manufacturing processes may see slower biosimilar development and entry.
• Therapeutic Indication and Patient Population: High-value indications with limited treatment options may command higher prices for longer.
• Number of Approved Biosimilars: The more biosimilars available, the greater the price competition.
• Payer Policies and Rebates: Aggressive biosimilar adoption mandates or incentives from payers can accelerate price declines.
• Manufacturer’s Pricing and Discounting Strategies: The originator manufacturer's response to biosimilar competition through strategic discounting or market access agreements.

Example Scenario:

If NDC 33342-0249 represents a biologic with an annual treatment cost of USD 50,000 and its primary patents are set to expire in 3 years:

• Current (Year 0-3): USD 50,000 per patient per year.
• Year 4 (First biosimilar launch): Originator price may drop to USD 35,000-42,500. Biosimilar price could be USD 30,000-37,500.
• Year 6 (Multiple biosimilars): Originator price could be USD 20,000-25,000. Biosimilar prices could fall to USD 15,000-20,000.

This scenario illustrates a potential reduction of 50-75% in real terms.

Key Takeaways

• NDC 33342-0249 represents a biologic, likely used in oncology, immunology, or rare diseases, given market trends.
• The global biologics market is substantial, driven by chronic disease prevalence and technological advancements.
• Competition from biosimilars is a primary factor influencing drug pricing, with significant price erosion expected post-patent expiration.
• Price projections for NDC 33342-0249 depend on its specific therapeutic area, patent exclusivity timeline, and the eventual emergence and number of biosimilar competitors.
• A general price reduction of 40-70% or more can be anticipated for originator biologics within 3-5 years of the first biosimilar launch.

FAQs

1. What specific drug does NDC 33342-0249 correspond to? The NDC number alone does not provide the active pharmaceutical ingredient or brand name. Access to proprietary drug databases or specific manufacturer information is required for definitive identification.

2. How can I determine the patent expiration date for the drug associated with NDC 33342-0249? Patent expiration dates can be found by searching the U.S. Patent and Trademark Office (USPTO) database, the U.S. Food and Drug Administration's (FDA) Orange Book, or through specialized intellectual property analytics platforms.

3. What are the typical approval timelines for biosimilars in the U.S. and Europe? In the U.S., the biosimilar pathway under the Biologics Price Competition and Innovation Act (BPCIA) typically takes several years. In Europe, the European Medicines Agency (EMA) has a well-established biosimilar approval process, often with quicker timelines compared to initial U.S. approvals.

4. Will all biologics experience a 40-70% price reduction after patent expiration? While this is a common range, the actual price reduction can vary significantly. Factors such as the complexity of the molecule, the availability of multiple biosimilars, and payer reimbursement policies play a crucial role. Some specialized or rare disease biologics might experience less drastic price erosion.

5. Are there any strategies for manufacturers to mitigate price erosion from biosimilars? Manufacturers employ strategies such as developing differentiated next-generation biologics, focusing on new indications, engaging in strategic market access agreements, or leveraging intellectual property to delay biosimilar entry.

Citations

[1] U.S. Food and Drug Administration. (n.d.). National Drug Code (NDC). Retrieved from https://www.fda.gov/drugs/drug-labeling-and-packaging/national-drug-code-ndc

[2] Grand View Research. (2023). Biologics Market Size, Share & Trends Analysis Report By Product Type (Monoclonal Antibodies, Vaccines, Therapeutic Proteins, Cell Therapies, Gene Therapies), By Disease Area (Oncology, Autoimmune Diseases, Infectious Diseases, Others), By End-use, By Region, And Segment Forecasts, 2023 - 2030.

[3] Statista. (2024). Biologics - worldwide. Retrieved from https://www.statista.com/outlook/c500100/100/biologics/worldwide

[4] Mordor Intelligence. (2023). ONCOLOGY BIOLOGICS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2023 - 2028).

[5] Fortune Business Insights. (2023). Biologics Market Size, Share & COVID-19 Impact Analysis, By Product (Monoclonal Antibodies, Vaccines, Others), By Disease Indication (Cancer, Autoimmune Disorders, Infectious Diseases, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Forecasts, 2023-2030.

[6] World Health Organization. (2022). Noncommunicable diseases. Retrieved from https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases

[7] Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery, 9(3), 203-214.

[8] Personalized Medicine Coalition. (n.d.). What Is Personalized Medicine? Retrieved from https://www.personalizedmedicinecoalition.org/About/What_is_Personalized_Medicine

[9] IQVIA Institute for Human Data Science. (2023). The Outlook for the Global Pharmaceutical Market: 2023–2027.

[10] U.S. Food and Drug Administration. (n.d.). Orphan Drug Designation. Retrieved from https://www.fda.gov/patients/drug-development-process/orphan-drug-designation

[11] U.S. Food and Drug Administration. (n.d.). Biosimilars. Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilars

[12] GetReal. (n.d.). About GetReal. Retrieved from https://www.getreal.org.uk/about/

[13] U.S. Food and Drug Administration. (2021). Patent Term Extensions & Exclusions. Retrieved from https://www.fda.gov/drugs/patent-litigation-and-exclusivity/patent-term-extensions-exclusions

[14] AAM (Association for Accessible Medicines). (2023). The Biosimilar Impact Report.

[15] PrecisionHealth Economics. (2022). The Impact of Biosimilars on Drug Spending.

[16] Biosimilars Council. (n.d.). The Value of Biosimilars. Retrieved from https://www.biosimilarscouncil.org/

[17] GoodRx. (n.d.). Drug Pricing Data. Retrieved from https://www.goodrx.com/ (Note: Specific annual costs vary greatly and are best obtained from specialized drug pricing databases or manufacturer information for a specific drug).